Skip to main content
BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%BTC / USDT107,400+2.19%ETH / USDT3,840+2.13%SOL / USDT182.40−1.99%BNB / USDT652.30+0.66%XRP / USDT2.2150+1.61%DOGE / USDT0.3850−1.79%TON / USDT5.240+2.34%AVAX / USDT42.60−2.07%LINK / USDT22.40+2.28%ADA / USDT1.0520−1.68%TRX / USDT0.3300+0.92%DOT / USDT8.420+2.93%
Pricing
Get started→
stocksJul 29, 2026, 10:35 AM

Boston Scientific Q2 Earnings Beat Estimates, But Full-Year Guidance Cut

Boston Scientific reported Q2 2026 adjusted EPS of $0.86, topping estimates, but lowered its full-year profit forecast below consensus.

BSX

Boston Scientific posted second-quarter adjusted earnings of $0.86 per share, beating the $0.83 consensus estimate. Net sales reached $5.44 billion, also above the expected $5.36 billion.

However, the company provided a weaker outlook. For the third quarter, it projects adjusted EPS of $0.80 to $0.82, missing the $0.84 estimate. Full-year 2026 adjusted EPS is now seen at $3.28 to $3.32, down sharply from the previous guidance of $3.34 to $3.41.

On a positive note, the organic net sales growth forecast was maintained at 5% to 6% for the full year.

Source: First Squawk